Loretta O Iniaghe1, Paul R Krafft2, Damon W Klebe3, Eric K I Omogbai4, John H Zhang5, Jiping Tang6. 1. Department of Physiology and Pharmacology, Loma Linda University, USA; Department of Pharmacology and Toxicology, University of Benin, Nigeria. 2. Department of Physiology and Pharmacology, Loma Linda University, USA; Department of Neurosurgery, Loma Linda University, Loma Linda, CA, USA. 3. Department of Physiology and Pharmacology, Loma Linda University, USA. 4. Department of Pharmacology and Toxicology, University of Benin, Nigeria. 5. Department of Physiology and Pharmacology, Loma Linda University, USA; Department of Anesthesiology, Loma Linda University, Loma Linda, CA, USA. 6. Department of Physiology and Pharmacology, Loma Linda University, USA. Electronic address: jtang@llu.edu.
Abstract
BACKGROUND AND PURPOSE: Edema formation, inflammation and increased blood-brain barrier permeability contribute to poor outcomes after intracerebral hemorrhage (ICH). This study examined the therapeutic effect of dimethyl fumarate (DMF), a fumaric acid ester that activates nuclear factor erythroid-2 related factor 2 (Nrf2) and Nrf2 heterodimerization effector protein musculo-aponeurotic fibrosarcoma-G (MAFG) in a murine ICH model. METHODS: Male CD-1 mice (n=176) were subjected to intrastriatal infusion of bacterial collagenase (n=126), autologous blood (n=18) or sham surgery (n=32). Four (4) animals not subjected to ICH (naive) were also included in the study. After ICH, animals either received vehicle, dimethyl fumarate (10 mg or 100 mg/kg) or casein kinase 2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA). Thirty-two mice also received scrambled siRNA or MAFG siRNA 24h before ICH. Brain water content and neurological function were evaluated. RESULTS: Dimethyl fumarate reduced Evans blue dye extravasation, decreased brain water content, and improved neurological deficits at 24 and 72 h after ICH. Casein kinase 2 inhibitor TBCA and MAFG siRNA prevented the effect of dimethyl fumarate on brain edema and neurological function. After ICH, ICAM-1 levels increased and casein kinase 2 levels decreased. Dimethyl fumarate reduced ICAM-1 but enhanced casein kinase 2 levels. Again, casein kinase 2 inhibitor TBCA and MAFG siRNA abolished the effect of dimethyl fumarate on ICAM-1 and casein kinase 2. Dimethyl fumarate preserved pNrf2 and MAFG expression in the nuclear lysate after ICH and the effect of dimethyl fumarate was abolished by casein kinase 2 inhibitor TBCA and MAFG siRNA. Dimethyl fumarate reduced microglia activation in peri-hematoma areas after ICH. The protective effect of dimethyl fumarate on brain edema and neurological function was also observed in a blood injection mouse model. CONCLUSION: Dimethyl fumarate ameliorated inflammation, reduced blood-brain barrier permeability, and improved neurological outcomes by casein kinase 2 and Nrf2 signaling pathways after experimental ICH in mice.
BACKGROUND AND PURPOSE:Edema formation, inflammation and increased blood-brain barrier permeability contribute to poor outcomes after intracerebral hemorrhage (ICH). This study examined the therapeutic effect of dimethyl fumarate (DMF), a fumaric acid ester that activates nuclear factor erythroid-2 related factor 2 (Nrf2) and Nrf2 heterodimerization effector protein musculo-aponeurotic fibrosarcoma-G (MAFG) in a murineICH model. METHODS: Male CD-1 mice (n=176) were subjected to intrastriatal infusion of bacterial collagenase (n=126), autologous blood (n=18) or sham surgery (n=32). Four (4) animals not subjected to ICH (naive) were also included in the study. After ICH, animals either received vehicle, dimethyl fumarate (10 mg or 100 mg/kg) or casein kinase 2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA). Thirty-two mice also received scrambled siRNA or MAFG siRNA 24h before ICH. Brain water content and neurological function were evaluated. RESULTS:Dimethyl fumarate reduced Evans blue dye extravasation, decreased brain water content, and improved neurological deficits at 24 and 72 h after ICH. Casein kinase 2 inhibitor TBCA and MAFG siRNA prevented the effect of dimethyl fumarate on brain edema and neurological function. After ICH, ICAM-1 levels increased and casein kinase 2 levels decreased. Dimethyl fumarate reduced ICAM-1 but enhanced casein kinase 2 levels. Again, casein kinase 2 inhibitor TBCA and MAFG siRNA abolished the effect of dimethyl fumarate on ICAM-1 and casein kinase 2. Dimethyl fumarate preserved pNrf2 and MAFG expression in the nuclear lysate after ICH and the effect of dimethyl fumarate was abolished by casein kinase 2 inhibitor TBCA and MAFG siRNA. Dimethyl fumarate reduced microglia activation in peri-hematoma areas after ICH. The protective effect of dimethyl fumarate on brain edema and neurological function was also observed in a blood injection mouse model. CONCLUSION:Dimethyl fumarate ameliorated inflammation, reduced blood-brain barrier permeability, and improved neurological outcomes by casein kinase 2 and Nrf2 signaling pathways after experimental ICH in mice.
Authors: K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima Journal: Biochem Biophys Res Commun Date: 1997-07-18 Impact factor: 3.575
Authors: Jingbo Pi; Yushi Bai; Jeffrey M Reece; Jason Williams; Dianxin Liu; Michael L Freeman; William E Fahl; David Shugar; Jie Liu; Wei Qu; Sheila Collins; Michael P Waalkes Journal: Free Radic Biol Med Date: 2007-03-12 Impact factor: 7.376
Authors: Crissey L Pascale; Alejandra N Martinez; Christopher Carr; David M Sawyer; Marcelo Ribeiro-Alves; Mimi Chen; Devon B O'Donnell; Jessie J Guidry; Peter S Amenta; Aaron S Dumont Journal: J Cereb Blood Flow Metab Date: 2019-06-20 Impact factor: 6.200
Authors: Manuj Ahuja; Navneet Ammal Kaidery; Lichuan Yang; Noel Calingasan; Natalya Smirnova; Arsen Gaisin; Irina N Gaisina; Irina Gazaryan; Dmitry M Hushpulian; Ismail Kaddour-Djebbar; Wendy B Bollag; John C Morgan; Rajiv R Ratan; Anatoly A Starkov; M Flint Beal; Bobby Thomas Journal: J Neurosci Date: 2016-06-08 Impact factor: 6.167
Authors: Ayla Hoogendoorn; Thomas D Avery; Jiahe Li; Christina Bursill; Andrew Abell; Peter M Grace Journal: Trends Pharmacol Sci Date: 2021-02-19 Impact factor: 14.819